Use of an Inactivated Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants

Abstract

Inactivated varicella vaccine given before hematopoietic-cell transplantation and during the first 90 days thereafter reduces the risk of zoster. The protection correlates with reconstitution of CD4 T-cell immunity against varicella-zoster virus.